AffaMed Therapeutics Dextenza receives Macau, China approval to treat ocular inflammation and pain following ophthalmic surgery
AffaMed Therapeutics (AffaMed), a global clinical-stage biopharmaceutical company, announced that Dextenza has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery. In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of Dextenza in Greater China, South Korea, and certain ASEAN markets. Dextenza is currently approved in the US for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis. Dr. Dayao Zhao, CEO of AffaMed commented: "We are encouraged by the Macau government
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
